Skip to main content
. Author manuscript; available in PMC: 2024 Dec 1.
Published in final edited form as: Pharmacol Ther. 2023 Nov 10;252:108561. doi: 10.1016/j.pharmthera.2023.108561

Table 2:

Clinical trials of RXR and RAR agonists in solid tumors

Tumor Drug Target Phase Status ClinicalTrials.gov
Non-melanoma Skin Cancer Vitamin D RXR-VDR - Not yet recruiting NCT05550766
13-Cis retinoic acid RAR - Completed NCT00025012
UAB30 RXR I Recruiting NCT03327064
Melanoma ATRA RARα II Active NCT02403778
13-Cis retinoic acid RAR - Completed NCT00025012
Non-Small Cell Lung Cancer IRX4204 with Erlotinib RXRs I Suspended NCT02991651 *
NRX194204 RXRs II Unknown NCT00964132
Bexarotene RXR I/II Terminated NCT00153842
Bexarotene RXR I Completed NCT01116622
Bexarotene RXR III Completed NCT00050973
Bexarotene with erlotinib RXR - Completed NCT00125372 *
Bexarotene with erlotinib RXR II Completed NCT00411632 *
Bexarotene with erlotinib RXR II Completed NCT00125359 *
Bexarotene with carboplatin and paclitaxel RXR III Completed NCT00050960 *
Bexarotene with gefitinib RXR I/II Completed NCT00238628 *
Bexarotene with ATRA RXR II Unknown NCT00514293 *
ATRA RAR III Unknown NCT01041833
13-Cis retinoic acid RAR II Completed NCT00002586
ATRA RARα II Completed NCT00617409
ATRA RARα II Completed NCT01048645
Myeloma Bexarotene and CS-7017 RXR-PPARγ I Terminated NCT01504490
Breast Cancer UAB30 RXR I Active NCT02876640
Bexarotene RXR I Completed NCT03323658
Bexarotene RXR II Completed NCT00003752
Bexarotene (in TNBC) RXR I Recruiting NCT04664829
Bexarotene (prevention) RXR I Completed NCT00055991
9-Cis retinoic acid RAR I Completed NCT00001504
ATRA RARα II Recruiting NCT04113863
Neuroblastoma Spironolactone RXRγ II Recruiting NCT05754684
13-Cis retinoic acid RAR I Completed NCT01208454
Retinoic Acid with Onalta RXR II Withdrawn NCT01048086 *
Prostate Cancer NRX194204 RXRs II Completed NCT01540071
Thyroid Cancer Bexarotene RXR I Completed NCT00718770
Head and neck cancer 13-Cis retinoic acid RAR III Completed NCT03370367
Bexarotene RXR I Completed NCT01116622
Cervical tumors 13-Cis retinoic acid RAR III Completed NCT00001073
Esophagus Bexarotene RXR I Completed NCT01116622

ATRA, all-trans retinoic acid; TNBC, Triple-negative breast cancer

*

: The RAR or RXR agonists were tested in combination with other drugs that are not known to activate these receptors.